Austria

Austria remains a restrictive jurisdiction for classical psychedelics. Public legal sources support research access and controlled exceptional routes, not ordinary medical care for psilocybin, LSD, MDMA, DMT or related compounds.

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Austria.

1
Austria is still research-first for classical psychedelics, with no routine authorised care pathway identified for psilocybin, MDMA, LSD or DMT.
2
Spravato changed the access picture: Austria now has a real but narrow public reimbursement route for esketamine in treatment-resistant depression.
3
Off-label ketamine exists in specialist practice, but it should not be treated as the same thing as an authorised antidepressant pathway.
4
Vienna is the national centre, linking BASG/AGES, MedUni Vienna, AKH, University of Vienna and the main psilocybin and ketamine research signals.
5
The clearest current classical-psychedelic trial signal is the Vienna psilocybin anti-anhedonia and imaging study.
6
Near-term progress is most likely to come from trials, esketamine implementation data and specialist service capacity, not from broad legal reform.

Research Snapshot

Blossom currently tracks 14 psychedelic clinical trials connected to Austria, including 5 active studies.

Active trials: 5
Total trials: 14
Stakeholders: 1
Events: 0

Top Compounds

Esketamine(10)
Ketamine(6)
Psilocybin(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

Austria remains restrictive for classical psychedelics, with no routine medical access identified for psilocybin, MDMA, LSD, DMT, ayahuasca, ibogaine or mescaline outside authorised research or exceptional non-generalisable routes. The clear patient-access route is Spravato, which entered Austria's reimbursement code in August 2024 under strict RE1 criteria. Racemic ketamine is an authorised anaesthetic with off-label psychiatric use and less predictable funding.

View trials→View stakeholders→Open access guide→

Regulatory Status

Austria remains restrictive for classical psychedelics. The national framework rests on the Suchtmittelgesetz and implementing regulations, with DMT, LSD, MDMA, mescaline, psilocin and psilocybin listed in Annex V.1 of the Suchtgiftverordnung and section 27 SMG expressly covering psilocybin- and psilocin-containing mushrooms in misuse-related contexts. No general medical authorisation or routine reimbursement route was identified for psilocybin, LSD, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca or mescaline. Esketamine is different: Spravato is EMA-authorised and entered Austria's reimbursement code from August 2024 under strict RE1 criteria. Racemic ketamine is an authorised anaesthetic but psychiatric use remains off-label.

History of Research in Austria

Austria's baseline is prohibitionary rather than reform-led. The modern framework sits under the Suchtmittelgesetz, the Suchtgiftverordnung and the Psychotropenverordnung, with classical psychedelics kept under narcotic-substance control rather than carved out into a special medical category. # # #

Contemporary clinical activity started more clearly with ketamine and esketamine than with psilocybin or MDMA. Austrian psychiatry incorporated esketamine into treatment-resistant depression discussions before there was comparable national infrastructure for classical psychedelics. # #

The decisive access milestone was reimbursement. Spravato's August 2024 entry into the Erstattungskodex created a nationally visible outpatient payer route, but only under strict RE1 criteria that require hospital initiation, specialist continuation and reassessment. # #

The newer phase is cautious research beyond ketamine-class compounds. MedUni Vienna publicly lists ketamine and psilocybin in its fast-acting antidepressants work, and University of Vienna project infrastructure now links psilocybin to hedonic response, brain dynamics and neuroplasticity. # # #

Vienna

Vienna is Austria's clear centre. It brings together BASG/AGES, MedUni Vienna, AKH, University of Vienna and the main current psilocybin and ketamine research signals. If one city matters for professional monitoring, it is Vienna. # # # #

MedUni Vienna is the clinical and translational anchor. Its psychiatry department describes esketamine use in treatment-resistant depression and lists ketamine and psilocybin in its fast-acting antidepressants research focus. # #

University of Vienna adds a cognitive-neuroscience layer through a project on hedonic response, brain network dynamics and neuroplasticity, explicitly connected to psilocybin and collaboration with the Medical University of Vienna. #

Outside Vienna, Klinikum Wels-Grieskirchen is a useful service signal because it describes esketamine treatment that starts in hospital and can continue on an outpatient basis. It is a secondary access node, not the national research centre. #

Research Focus

Mood disorders remain the main Austrian focus. MedUni Vienna's fast-acting antidepressants group explicitly centres treatment-resistant depression and rapid-acting interventions, with ketamine and psilocybin both present in its research profile. # #

The clearest classical-psychedelic study signal is the Vienna psilocybin anti-anhedonia trial. Public listings describe an open-label, cross-over functional MRI study using psilocybin and risperidone in people with depression and anhedonia as well as healthy controls, with Medical University of Vienna sponsorship and University of Vienna collaboration visible in the surrounding project architecture. # #

Ketamine research is broader. Austrian Science Fund materials describe ketamine work in obsessive-compulsive disorder and stress symptoms, while trial listings show ketamine-in-OCD activity connected to Austria. This sits closer to translational psychiatry than to access expansion. # #

BASG's accelerated mononational clinical-trial route, introduced in April 2025, is not psychedelic-specific, but it could make Austria more practical for investigator-led studies. That matters most for Vienna, where the relevant clinical, imaging and regulatory expertise is concentrated. # # #

Key Milestones

2009

Austria implements compassionate use in national medicines law through section 8a of the Austrian Medicinal Products Act.

2019

Spravato receives EU marketing authorisation for treatment-resistant depression.

2021

Austrian treatment-resistant depression consensus work incorporates esketamine into specialist discussion of rapid-acting antidepressants.

Nov 2023

OEGPP publishes its esketamine position paper, including treatment-resistant depression and psychiatric-emergency positioning.

1 Aug 2024

Spravato enters Austria's Erstattungskodex under RE1 conditions, creating a defined outpatient public reimbursement route for qualifying patients.

22 Apr 2025

BASG introduces an accelerated process for mononational clinical-trial applications, with a target timeline for deficiency-free applications.

1 Oct 2025

The University of Vienna psilocybin project on hedonic response, brain dynamics and neuroplasticity becomes active.

1 Nov 2025

Public trial listings date first enrolment or study start of the Vienna psilocybin anti-anhedonia study to November 2025.

Mar 2026

Public trial listings show the Vienna psilocybin anti-anhedonia study as recruiting.

Future Outlook

Austria is most likely to change through evidence generation and service implementation rather than top-level legal reform. Vienna's psilocybin study, ketamine imaging work and ketamine-in-OCD activity are the near-term research watch items. # # # #

On access, the practical growth area is esketamine. Spravato already has authorisation and an EKO reimbursement route, so expansion depends on service capacity, referral practice, specialist training and real-world outcomes rather than a new legal category. # # # #

Classical psychedelic care is likely to remain confined to trials or exceptional, non-generalisable mechanisms unless there is an upstream EMA authorisation and a later Austrian reimbursement decision. BASG's compassionate-use and named-patient-use materials do not currently establish a public psychedelic access programme. # # #